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Abstract
Background: Forced expiratory volume in one second (FEV1) is used to diagnose and establish a prognosis in chronic 
obstructive pulmonary disease (COPD). Using multi-dimensional scores improves this predictive capacity.Two 
instruments, the BODE-index (Body mass index, Obstruction, Dyspnea, Exercise capacity) and the HADO-score (Health, 
Activity, Dyspnea, Obstruction), were compared in the prediction of mortality among COPD patients.
Methods: This is a prospective longitudinal study. During one year (2003 to 2004), 543 consecutively COPD patients 
were recruited in five outpatient clinics and followed for three years. The endpoints were all-causes and respiratory 
mortality.
Results: In the multivariate analysis of patients with FEV1 < 50%, no significant differences were observed in all-cause 
or respiratory mortality across HADO categories, while significant differences were observed between patients with a 
lower BODE (less severe disease) and those with a higher BODE (greater severity). Among patients with FEV1 ≥ 50%, 
statistically significant differences were observed across HADO categories for all-cause and respiratory mortality, while 
differences were observed across BODE categories only in all-cause mortality.
Conclusions: HADO-score and BODE-index were good predictors of all-cause and respiratory mortality in the entire 
cohort. In patients with severe COPD (FEV1 < 50%) the BODE index was a better predictor of mortality whereas in 
patients with mild or moderate COPD (FEV1 ≥ 50%), the HADO-score was as good a predictor of respiratory mortality as 
the BODE-index. These differences suggest that the HADO-score and BODE-index could be used for different patient 
populations and at different healthcare levels, but can be used complementarily.
Background
Forced expiratory volume in one second (FEV1) is an
essential measure for diagnosing chronic obstructive pul-
monary disease (COPD) and in establishing its severity
and prognosis. Traditionally, the two most important
prognostic factors in the COPD have been FEV1 and age
[1,2]. Other variables, such as dyspnea [3], malnutrition
[4], hospitalization related to COPD exacerbation [5],
exercise capacity [6], physical activity [7], pulmonary
hypertension [8], inspiratory capacity [9], lung density
measurements by computed tomography [10], muscle
mass [11], health-related quality of life [12], and other
markers [13], have also proved to be individual, effective
prognostic factors.
Simultaneously employing several variables improves
the assessment of patients with COPD [11], and grouping
these variables improves prognostic capacity compared
with traditional classifications of COPD severity based
exclusively on FEV1. In this regard, the BODE-index
(Body mass index, Obstruction, Dyspnea, Exercise capac-
ity) has proved to be a good predictor of respiratory and
all-cause mortality [14]. The HADO-score (Health,
Activity, Dyspnea, Obstruction) is another multidimen-
sional prognostic index that works well for predicting all-
cause mortality [15].
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The aim of this study was to compare the predictive
capacity of the BODE-index and the HADO-score for all-
cause and respiratory mortality in a large group of ambu-
latory patients with varying severity of COPD.
Methods
Between January 2003 and January 2004, we recruited all
patients previously diagnosed with COPD who regularly
visited an outpatient clinic affiliated with the Hospital
Galdakao-Usansolo, a teaching hospital with a catchment
area of 300,000 inhabitants that could carry out the tests
relevant to the study.
Consecutive patients were included in the study if they
had been diagnosed with COPD at least six months pre-
viously and had been under treatment for at least six
months. Patients had to be stable (no increase in respira-
tory symptoms or changes in treatment) for six weeks
prior to inclusion. Other inclusion criteria were FEV1 <
80% of the predicted value, with an FEV1/FVC quotient
<70% and a negative bronchodilation test with FEV1
change <15% of the baseline value or <200 ml. The func-
tional parameters used were those obtained following
bronchodilation. Patients were not eligible for the study if
they had been diagnosed with asthma, had extensive pul-
monary tuberculosis or neoplastic processes, were suffer-
ing from psychiatric or neurological problems that might
prevent effective collaboration, or had hearing or other
problems that impeded accurate communication.
The study was approved by the research committee of
the Hospital Galdakao-Usansolo. Patients provided
informed consent to take part in the study. All patients
were followed for three years.
The BODE-index is made up of four variables (body
mass index, FEV1, dyspnea, and a six-minute walking
test). Its score ranges from 0 to 10 points in such a way
that the higher the score the higher the severity [14]. The
HADO-score is made up of four variables (the answer to
a single, general, self-rated health question; self-rated
level of physical activity; dyspnea; and FEV1). Its score
ranges from 0 to 12, with a lower score indicating a higher
severity and therefore a worse prognosis [15] (Table 1).
Patients were asked about their level of dyspnea using a
five-degree modified Medical Research Council scale [16]
and the scale adapted from Fletcher [17]: Degree 1, 'dysp-
nea only with intense and strenuous exercise'; Degree 2,
'capable of walking at the same pace as other people my
age on the level'; Degree 3, 'capable of walking on the level
at my own speed without dyspnea, but incapable of walk-
ing at the same pace as people my age'; Degree 4, 'dyspnea
after walking slowly for 100 meters'; and Degree 5, 'dysp-
nea when resting or after slight effort such as getting
dressed'.
General health was assessed by means of the question,
'In general, would you say your health is...'. The five possi-
ble answers were poor, fair, good, very good, and excellent.
Body mass index (BMI) was calculated by dividing
weight in kilograms by the square of height in meters.
The six-minute walking test (6MWT) was carried out
following American Thoracic Society (ATS) rules [18].
The best result was selected from two tests conducted
with a 30-minute break between them.
Levels of physical activity were assessed on a scale from
0 to 3: 0) 'doesn't leave the house, life is limited to the bed
or armchair, or to doing some domestic chores', or 'leaves
the house, but walks less than 100 meters'; 1) 'leaves the
house and walks a few hundred meters, runs errands, but
does not walk regularly'; 2) 'engages in physical activity in
the vegetable garden', or 'takes walks for up to 8 kms, no
less than five days a week'; and 3) 'takes walks regularly
for longer than 8 kms, no less than five days a week', or
'practices sports'.
Spirometry was conducted following criteria from
Spanish Pneumology and Thoracic Surgery Society
(SEPAR) [19], with a Master Scope-PC spirometer (Erich
Jaeger GmbH & Co, KG, Wuerzburg, Germany). Theo-
retical values were those prescribed by the European
Community for Steel and Coal [20].
W e also measured the number of pack-years of ciga-
rette smoking, established as the product of years as a
smoker and the average number of cigarettes smoked per
day, divided by 20.
Comorbidities were determined by reviewing the
patients' clinical histories, applying the Charlson index
[21]. This index has been developed to predict the mor-
tality of patients with chronic disease. It generates a score
that is proportional to the disease-related risk of death.
Main outcomes
Vital status was initially determined by telephone calls
made to patients or their next of kin. All reported deaths
and dates of deaths were confirmed by reviewing medical
reports, by examination of the hospital database and pub-
lic death registries, or both. Deaths were considered con-
firmed if the record matched the subject on name, sex,
a nd da t e  of  bi rt h.  In al l cases,  t he  ca use  o f  dea t h was
based on the hospital reports and public death registries.
In cases in which death occurred out of the hospital, the
researchers surveyed relatives and the primary care doc-
tor. If the cause of death still remained unclear, a commit-
tee formed by some authors decided what the mortality
was caused by.
Statistical analysis
We present mean and standard deviations for continuous
variables and frequencies and percentages for categoricalEsteban et al. BMC Medicine 2010, 8:28
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variables. We used the Chi-square and Fisher's exact tests
to evaluate associations among categorical variables.
Logistic regression models were used to study the abil-
ity of the BODE-index and HADO-score on vital status.
Both all-cause and respiratory-related mortalities were
evaluated. Additional analyses were performed using a
FEV1 cut-off point of 50% to categorize patients as severe
versus moderate/mild severity.
We performed a multivariate analysis, adjusting by age,
cigarette packs/year, number of hospitalizations in the
previous two years, and comorbidities measured by
Charlson comorbidity index.
We computed the C statistic using logistic regression
models to study the final predictive ability of the model.
In these analyses, the C statistic is a mathematical func-
tion of the sensitivity and specificity of the score in classi-
fying patients by means of a logistic regression model as
either dying or surviving. The null value for the C statistic
is 0.5, with a maximum value of 1.0 (higher values indi-
cate better health).
All effects were considered significant at P < 0.05 unless
otherwise noted. All statistical analyses were performed
using SAS for Windows statistical software, version 8.2.
(SAS Institute, Inc., Carey, NC, USA).
Results
From a total of 808 consecutive COPD patients seen in
one of the clinics, 265 were excluded from the study: 48 of
these were not able to carry out the 6MWT, 63 had neo-
plasias (14 with pulmonary neoplasias), 30 had extensive
bronchiectasis, 15 had fibrothorax, 18 had silicosis, 14
had extensive sequelae of pulmonary tuberculosis, 12
could not complete valid spirometry, 12 had senile
dementia or Alzheimer's disease, 6 had a psychiatric
pathology, 25 had miscellaneous other pulmonary and
extrapulmonary reasons, and 22 refused to take part.
Table 1: Variables and point values used in BODE-index and HADO score
BODE-index value HADO-score value
FEV1% FEV1%
≤65 0 ≤65 3
50 to 64 1 50 to 64 2
36 to 49 2 36 to 49 1
≤35 3 ≤35 0
Dyspnea scale Dyspnea scale
0  t o  1 013
2122
3231
43 4  t o  5 0
6 MWT (m) Physical Activity
≥ 3 5 0 033
250 to 349 1 2 2
150 to 249 2 1 1
≤ 1 4 9 300
BMI Health status
>21 0 very good/excelent 3
≤21 1 good 2
fair 1
bad 0
- FEV1% = forced expiratory volume in one second (% of predicted). Based on the stages of the American Thoracic Society.
- Dyspnea scale. 16,17
- Physical Activity: 0) 'doesn't leave the house, life is limited to the bed or armchair, or to doing some domestic chores', or 'leaves the house, 
but walks less than 100 meters'; 1) 'leaves the house and walks a few hundred meters, runs errands, but does not walk regularly'; 2) 'engages 
in physical activity in the vegetable garden', or 'takes walks for up to 8 kms, no less than five days a week'; and 3) 'takes walks regularly for 
longer than 8 kms, no less than five days a week', or 'practices sports'
- 6MWT = distance in meters walked in six minutes.Esteban et al. BMC Medicine 2010, 8:28
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This left 543 eligible patients; their characteristics are
listed in Table 2. The sample was made up almost exclu-
sively of men (96%). Patients had COPD of moderate
severity (mean FEV1%, 55%) with a Charlson index of 2.4;
36% of the patients were admitted to the hospital at least
once in the two years before being included in the study.
Seventy-one patients (13.1%) died during the three-year
follow-up period, primarily due to respiratory (45.1%),
cardiovascular (18.3%), and cancer (12.7%) related condi-
tions. The patients who died during follow up were older,
had a significantly higher level of dyspnea, lower FEV1,
lower exercise capacity in the 6MWT, and had been
admitted to the hospital more often in the two years
before the study began than the survivors. All the vari-
ables that made up the BODE-index and the HADO-
score showed statistical differences between those
patients still alive or dead at three years. In addition, their
scores in the BODE-index and HADO-score showed sig-
nificantly greater disease severity.
In the univariate analysis, both the BODE-index and
the HADO-score were associated in their different cate-
gories with all-cause or respiratory mortality (Table 3).
To explore the impact of FEV1 on prognosis, we divided
the sample into two groups, FEV1 ≥ 50% and FEV1 < 50%.
Among patients with FEV1 < 50%, the greater the severity
of the BODE-index and the HADO-score, the higher the
mortality. However, this trend was statistically significant
only for the BODE- index. Among patients with FEV1 ≥
50%, a direct association was again seen between the
severity of the BODE-index and HADO-score and both
respiratory and all-cause mortality, but in this case the
trend was statistically significant for both measures
(Table 4).
In the multivariate analysis of the total sample of 543
patients, patients with HADO scores reflecting moderate
(score 5 to 7) or mild (score 8 to 12) severity of COPD had
low all-cause mortality after adjustment by age, hospital-
izations in the two previous years, and comorbidities.
Among patients with moderate HADO scores, the odds
ratio (OR) for all-cause mortality was 0.39 (95% confi-
dence interval (CI), 0.21 to 0.73), and was even lower
(OR, 0.20; 95% CI, 0.07 to 0.60) for those with mild
HADO scores compared to the most severe HADO cate-
gory. For respiratory mortality, a HADO-score reflecting
mild COPD severity also predicted low mortality (OR,
0.18; 95% CI, 0.04 to 0.86). BODE-index scores reflecting
mild COPD severity also predicted significantly lower all-
cause mortality compared to the most severe category
(score 7 to 10), while a moderate BODE-index (score 5 to
6) was not a statistically significant predictor of all-cause
mortality (OR, 0.55; 95% CI, 0.17 to 1.73). For respiratory
mortality, the multivariate analysis revealed statistically
significant differences between all the categories com-
pared with the most severe category. (Table 5)
In the multivariate analysis that included only patients
with FEV1 < 50%, HADO scores reflecting moderate and
mild COPD severity were not significantly better predic-
tors of all-cause or respiratory mortality compared with
the reference category of severe HADO-score (0 to 4),
while significant differences in all-cause and respiratory
mortality were observed between patients with lower
BODE- index scores (less severe disease) compared to
those with the highest scores (most severe disease).
Among patients with FEV1 ≥ 50%, those with mild to
moderate HADO scores had significantly lower all-cause
and respiratory mortality than those with severe HADO
scores. With the BODE-index, significant differences
were observed only for all-cause mortality (Table 6).
Figure 1 and Table 7 show the area under the curve
(AUC) for the overall sample and both subsamples (FEV1
< 50% and FEV1 ≥ 50%), not being the BODE-index bet-
ter than the HADO-score or vice versa.
Discussion
This three-year study of 543 patients with COPD rein-
forces earlier findings that both the HADO-score and the
BODE-index are good predictors of all-cause and respira-
tory mortality. However, differences appear between the
two when applied to patients with different severity of
COPD, as measured by FEV1%. In patients with the most
severe disease (FEV1 < 50%), the BODE-index is a better
predictor than the HADO-score of all-cause and respira-
tory mortality, whereas in patient with less severe disease
(FEV1 ≥ 50%), the HADO-score is as good predictor of
respiratory mortality as the BODE-index.
The HADO-score and BODE-index arose from differ-
ent patient populations. This is likely to determine their
characteristics, qualities, and where each is most appro-
priately used. The BODE-index originated in a study of a
sample of patients (recruited in hospitals), who are gener-
ally more seriously ill. In the studies defining these mea-
sures, almost 70% of the patients in the BODE-index
cohort had an FEV1 < 50%, compared with 34% of those in
the HADO-score cohort. In contrast, the HADO-score
emerged from outpatient pneumology clinics, where the
spectrum of COPD severity is wider, and generally lower,
than it is among hospitalized patients. The HADO-score
is also simpler to determine, which reflects the difficulty
of conducting complex or time-consuming tests in the
primary care setting.
Two variables shared by both measures are essential
predictors of mortality among patients with COPD: FEV1
[1,2] and dyspnea. Although their importance has been
questioned by some, it has been suggested that dyspnea isEsteban et al. BMC Medicine 2010, 8:28
http://www.biomedcentral.com/1741-7015/8/28
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Table 2: Baseline characteristics of the study participants and characteristics by vital status after three years of follow up
All Patients
(n = 543)
Alive
(n = 472)
Dead
(n = 71)
P-Value
Age, yr 68.3 ± 8.3 67.8 ± 8.4 72.1 ± 6.5 <.001
Men 522 (96.1%) 452 (95.76%) 70 (98.59%) 0.34
FEV1, L 1.46 ± 0.44 L 1.50 ± 0.44 1.20 ± 0.36 <.001
FEV1% 55.0 ± 13.3 55.9 ± 13 49 ± 14 <.001
FEV1/VC 54.5 ± 9.32 54.7 ± 9.2 53.1 ± 10.5 0.16
Dyspnea scale <.001
1 69 (12.7%) 62 (13.1%) 7 (9.9%)
2 264 (48.6%) 245 (51.9%) 19 (26.8%)
3 166 (30.6%) 136 (28.8%) 30 (42.3%)
4-5 44 (8.1%) 29 (6.1%) 15 (21.1%)
Distance walked in six 
minutes (m)
408.9 ± 92.4 420.1 ± 86.5 334 ± 96.6 <.001
Charlson index 2.4 ± 1.4 2.3 ± 1.3 3.3 ± 1.6 <.001
BMI 28.3 ± 4.4 28.4 ± 4.4 27.4 ± 4.8 0.09
Smoking habit 0.84
Current smokers 114 (20.9%) 101 (24.1%) 13 (18.3%)
Ex-smokers 414 (76.2%) 358 (75.8%) 56 (78.9%)
Never smoked 15 (2.8%) 13 (2.7%) 2 (2.8%)
Mean pack/year, 
SD
48.2 ± 26.5 47.7 ± 26.3 51.1 ± 28 0.32
BODE index 2.8 ± 1.8 2.6 ± 1.6 4.2 ± 1.9 <.001
HADO score 6.8 ± 2.1 7 ± 2 5.6 ± 2.1 <.001
Previous admissions <.001
0 402 (74%) 370 (78.4%) 32 (45.1%)
1 88 (16.2%) 65 (13.8%) 23 (32.4%)
≥2 53 (9.8%) 37 (7.8%) 16 (22.5%)
Distance walked in 6 
min (m)
<0.001
≤ 149 5 (0.92%) 4 (0.85%) 1 (1.41%)
150 to 249 27 (4.97%) 14 (2.97%) 13 (18.31%)
250 to 349 91 (16.76%) 66 (13.98%) 25 (35.21%)
≥ 350 420 (77.35%) 388 (82.20%) 32 (45.07%)
Physical activity <0.001
0 28 (5.16%) 17 (3.60) 11 (15.49)
1 54 (9.94%) 45 (9.53%) 9 (12.68%)
2 365 (67.22%) 315 (66.74%) 50 (70.42%)
3 96 (17.68%) 95 (20.13%) 1 (1.41%)
General Health <0.001
Bad 52 (9.58%) 45 (9.53%) 7 (9.86%)
Fair 293 (53.96%) 256 (54.24%) 37 (52.11%)
Good 178 (32.78%) 151 (31.99%) 27 (38.03%)
Excellent to Very 
good
20 (3.68%) 20 (4.24%) 0 (0%)Esteban et al. BMC Medicine 2010, 8:28
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likely to be a better mortality predictor than FEV1 [3],
though this has not been always replicated [22]. The dif-
ferent variables in the two measures are the patient's per-
ception of his or her general health and self-reported
physical activity in the HADO-score and BMI and the
6MWT in the BODE-index.
In our application of the HADO score, we introduced a
single question to gauge a patient's sense of his or her
level of health ('In general, would you say your health
is...'). This question has proved to have good reproduc-
ibility, reliability, and strong concurrent and discrimina-
tory scale performance with an established health status
measure (SF-12) [23]. Moreover, it has been shown that
this single health-related question can stratify patients
with different risks for adverse outcomes such as mortal-
ity and the use of health resources [24]. A meta-analysis
suggests a strong association between self-perceived
health status and mortality, even after adjustment for key
covariates such as functional status, depression, and co-
morbidity, with individuals reporting poor health having
higher mortality than their counterparts reporting excel-
lent health (OR, 1.74; 95% CI, 1.51 to 2.02) [25].
The BODE-index includes BMI as a variable. It has
been shown that BMI < 20 kg/m2 constitutes an indepen-
dent predictive factor related to COPD mortality [4]. In a
study by Chailleux et al., the prevalence of malnutrition
in patients with severe COPD who required home oxygen
therapy ranged from 23% for men to 30% for women
[26].The prevalence of malnutrition appears to be lower
in the Mediterranean area. In a study of 3,126 patients,
FEV1% <0.001
≤ 35 45 (8.29%) 31 (6.57%) 14 (19.72%)
36 to 50 140 (25.78%) 119 (25.21%) 21 (29.58%)
51 to 64 217 (39.96%) 189 (40.04%) 28 (39.44%)
≥ 65 141 (25.97%) 133 (28.18%) 8 (11.27%)
BMI 0.02
≤ 21 28 (5.16%) 20 (4.24%) 8 (11.27%)
>21 515 (94.84%) 452 (95.76%) 63 (88.73%)
Data are presented as mean ± SD or number (%)
FEV1% = % FEV1 of predicted value.
Dyspnea from Fletcher 12
BMI: Body mass index.
Physical Activity: 0) 'doesn't leave the house, life is limited to the bed or armchair, or to doing some domestic chores', or 'leaves the house, 
but walks less than 100 meters'; 1) 'leaves the house and walks a few hundred meters, runs errands, but does not walk regularly'; 2) 'engages 
in physical activity in the vegetable garden', or 'takes walks for up to 8 kms, no less than five days a week'; and 3) 'takes walks regularly for 
longer than 8 kms, no less than five days a week', or 'practices sports'.
Table 2: Baseline characteristics of the study participants and characteristics by vital status after three years of follow up 
Table 3: All-cause and respiratory mortality in the entire cohort
All-Cause Mortality
(n = 71)
P-value Respiratory Mortality
(n = 32)
P-value
BODE index <.0001 <.0001
0 to 2 (260) 14 (5.4%) 5 (2%)
3 to 4 (193) 26 (13.5%) 13 (7.2%)
5 to 6 (71) 24 (33.8%) 9 (16.1%)
7 to 10 (19) 7 (36.8%) 5 (41.7%)
HADO score <.0001 <.0001
0 to 4 (73) 23 (32.39%) 14 (43.75%)
5 to 7 (265) 35 (49.30%) 11 (34.38%)
8 to 12 (205) 13 (18.31%) 7 (21.88%)
Data are presented as number (%)
For the BODE index, higher scores indicate greater severity of disease; for the HADO score, lower scores indicate greater severity of diseaseEsteban et al. BMC Medicine 2010, 8:28
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50% of whom had a FEV1 < 50%, it was about 7% [27]. In
the ambulatory setting, BMI offers limited prognostic
value, since most patients seen in this setting have mild or
moderate COPD, which generally does not cause malnu-
trition leading to BMI < 20 kg/m2. On the other hand,
among patients with severe COPD, it is probably appro-
priate to carry out a precise measure of body composi-
tion, since it has been observed that lower fat-free mass is
associated with higher mortality [28]. Since determining
body composition would increase the complexity of
obtaining the data for the prognostic index, its use should
be reserved for patients with severe disease and should be
exclusively handled in the hospital or specialized outpa-
tient clinics.
The assessments of activity used in the two measures
are also quite different. Self-reported physical activity,
used in the HADO-score, is a behaviour (the activity the
patient makes) that is quite simple to evaluate. The
6MWT, used in the BODE-index, reflects exercise capac-
ity, a condition the patient reaches that allows him or her
to meet the requirements of daily life (what the patient is
able to do) [29]. The 6MWT is more difficult to measure.
Both concepts, physical activity and exercise capacity, are
indistinctly used in epidemiological studies.
Exercise capacity (as peak oxygen uptake, VO2 ) has
been associated with COPD mortality independent of
FEV1 and age [6]. Among patients with severe COPD, the
distance walked in six minutes has been shown to be an
independent and better predictor of mortality than FEV1
[30]. In a recent study, the 6MWT had a stronger associa-
tion with mortality (HR, 0.996; 95% CI, 0.993 to 0.999; P <
0.01) than did peak VO2 (HR, 0.971; 95% CI, 0.959 to
1.000; P = 0.050) [31].
Regarding physical activity, Garcia-Aymerich et al.
showed in a population-based cohort that among patients
with COPD, even slight physical activity (equivalent to
walking or bicycling for two hours per week) had impor-
tant consequences for the course of the disease, decreas-
ing by 30% to 40% the risk of hospitalization due to
COPD and the risk of respiratory mortality [7]. Interest-
Table 4: All-cause and respiratory mortality by BODE index and HADO score categories by FEV1%
All-Cause Mortality P-value Respiratory Mortality P-value
FEV1 ≥ 50% (n = 36) (n = 12)
BODE index <.0001 0.005
0 to 2 (256) 14 (5.5%) 5 (2%)
3 to 4 (83) 12 (14.4%) 5 (6.6%)
5 to 6 (19) 10 (52.6%) 2 (18.2%)
7 to 10 (0) 0 0
HADO score <.0001 <.0001
0 to 4 (11) 7 (63.6%) 5 (55.6%)
5 to 7 (157) 18 (11.5%) 2 (1.4%)
8 to 12 (190) 11 (5.8%) 5 (2.7%)
FEV1 < 50% (n = 35) (n = 20)
BODE index 0.02 0.05
0 to 2 (4) 0 0
3 to 4 (110) 14 (12.7%) 8 (7.7%)
5 to 6 (62) 14 (22.6%) 7 (12.7%)
8 to 10 (19) 7 (36.8%) 5 (29.4%)
HADO score 0.23 0.39
0 to 4 (62) 16 (25.8%) 9 (16.4%)
5 to 7 (108) 17 (15.7%) 9 (9%)
8 to 12 (15) 2 (13.3%) 2 (13.3%)
Data are presented as number (% of each category).
Note: For the BODE index, higher scores indicate greater severity of disease; for the HADO score, lower scores indicate greater severity of 
disease.Esteban et al. BMC Medicine 2010, 8:28
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ingly, a questionnaire, or even a single question, on physi-
cal activity have proved to have acceptable associations
with VO2 [32].
Despite the differences, both self-reported physical
activity and exercise capacity appear to offer similar
information concerning morbidity and mortality. Both
are good predictors of mortality [33].
The differences in the HADO-score and BODE-index
as predictors of mortality among patients with FEV1 <
50% is worth noting. Although both appear to behave
similarly when analyzed using ROC curves (Figure 1), the
multivariate analysis yields several differences. This could
be due to the cut-points chosen, or because the HADO-
score has only three categories of severity, compared to
four for the BODE-index.
One limitation of our study is that the sample was com-
posed almost entirely of men, which makes it impossible
to generalize the results to women as well. This reflects
the fact that in Spain, smoking was once for men only,
and women began smoking relatively recently. It is possi-
ble that the use of self-reported physical activity in creat-
ing the HADO-score could influence the results, since we
did not objectively measure the level of activity by accel-
erometers. Given the size of the cohort, this would have
been a difficult undertaking. The main goal of this work
was to study the functioning of both scores (BODE and
HADO) in patients with different severity. Apart from
using multidimensional scores, which is the main point of
this work, there is not any other alternative form of classi-
fying severity of COPD than using FEV1. Nevertheless,
this choice has some disadvantages since this division of
our sample (FEV1 < 50% vs FEV1 ≥ 50%) reduces the
number of deaths in each category and thus the power of
the study to detect differences between the BODE and
the HADO in their ability to predict mortality. But
besides that, we were able to detect differences.
Strengths of this study are the prospective collection of
data, up to three years of follow-up of a relatively large
cohort of COPD patients covering a wide range of sever-
ity of the disease and the evaluation of the utility of two
COPD-specific severity scales in relation to robust out-
comes, such as mortality.
Conclusion
Both the HADO-score and the BODE-index are sup-
ported by variables that have been shown to be consistent
predictors of mortality among patients with COPD. In
general, the two measures generally perform similarly.
However, the BODE-index yields better results among
patients with the most severe COPD (FEV1 < 50%), who
a r e  l i k e l y  t o  b e  a s s e s s e d  a t  t h e  h o s p i t a l  l e v e l .  A m o n g
patients with less severe disease (FEV1 ≥ 50%), who com-
prise the majority of patients with COPD and who are
generally seen in the outpatient or primary care setting,
the HADO-score is as good a predictor of respiratory
mortality, a crucial parameter in these patients, as the
BODE-index. The HADO-score is also easier to compile
in the outpatient and primary care settings. Therefore, we
propose that these instruments are appropriate for differ-
ent settings. The HADO-score offers a quick, simple
assessment suitable for use by practitioners seeing
patients with mild to moderate COPD and who do not
immediately require more thorough evaluation. The
B O D E - i n d e x  i s  m o r e  s u i t a b l e  f o r  t h e  e v a l u a t i o n  o f
Table 5: Multivariate logistic regression for mortality. Overall sample
All cause mortality Respiratory mortality
OR (95% CI) P-value OR (95% CI) P-value
HADO score
0 to 4 1 1
5 to 7 0.43 (0.25, 0.87) 0.002 0.23 (0.09, 0.59) 0.002
8 to 12 0.25 (0.10, 0.58) 0.001 0.26 (0.09, 0.77) 0.02
BODE index
0 to 2 0.12 (0.04, 0.38) 0.0004 0.05 (0.01, 0.23) < 0.001
3 to 4 0.23 (0.08, 0.70) 0.01 0.13 (0.03, 0.50) 0.003
5 to 6 0.53 (0.17, 1.70) 0.29 0.20 (0.05, 0.87) 0.03
7 to 10 1 1
Models were adjusted by age, previous hospital admissions and packs/year and Charlson Comorbidity Index.
Note: For the BODE index, higher scores indicate greater severity of disease; for the HADO score, lower scores indicate greater severity of 
diseaseEsteban et al. BMC Medicine 2010, 8:28
http://www.biomedcentral.com/1741-7015/8/28
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Table 6: All-cause and respiratory mortality according to severity of COPD (FEV1 < 50% vs. FEV1 ≥ 50%)
FEV1 < 50% FEV1 ≥ 50%
All-cause mortality Respiratory mortality All-cause ortality Respiratory mortality
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
HADO score
Severe 1 1 1 1
Mild to 
Moderate
0.83 (0.34, 1.98) 0.67 0.81 (0.28, 2.36) 0.70 0.03 (0.005, 0.16) <0.001 0.001 (0.0003, 0.05) < 0.001
BODE index
Mild 0.24 (0.07, 0.82) 0.02 0.17 (0.04, 0.74) 0.02 0.11 (0.04, 0.37) 0.003 0.23 (0.03, 1.75) 0.16
Moderate 0.40 (0.11, 1.47) 0.17 0.23 (0.05, 1.11) 0.07 0.22 (0.07, 0.71) 0.01 0.50 (0.06, 3.95) 0.50
Severe 1 1 1 1
Categories for HADO score: Severe (<5), Mild-Moderate (≥5); Categories for BODE store in patients with FEV < 50: Mild (≤4), Moderate (5 to 6), 
Severe (≥7). Levels for BODE score in patients with FEV >50; Mild (0 to 2); Moderate (3 to 4); Severe (>4). Models were adjusted by age, previous 
hospital admissions, packs/year and Charlson Comorbidity Index.
Figure 1 ROC Curves for mortality.
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patients with more severe COPD, who require more
accurate and specialized assessment requiring more
resources of time and personnel. That said, the use of
both indexes is not incompatible and they could even be
complementary in the different care levels.
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